

BIOEMTECH 5th ANNUAL PRECLINICAL WORKSHOP PROGRAMME

TIME/DAY	TUESDAY	WEDNESDAY	THURSDAY	FRIDAY	
08:45 - 09:15	Welcome coffee	Welcome coffee & Opening Remarks		Welcome coffee	
09:15 – 09:45		Roundtable of introductions for participants			
		Oncology Therapies Session	Going to the clinics Session	Sateliite Session Panel	
		Talk 1: Status of EBRT, CTX, IO, RLT	Talk 7: Phase 0: Fastest In-Patients trials Regulations, Execution and Possibilities	Satellite Panel Discussion: R&D in the RLT field - Ongoing & upcoming EU granted projects	
		Speaker: [TBD]	Speaker: Famke Van Renesse-Brouwer Business to Science Manager TRACER	Speakers: Group of 10' talks from different projects	
		10 min discussion	10 min discussion		
09:45 – 10:25	LAB TOUR DEMONSTRATIONS - GROUPS & LABS SOON TO BE ALLOCATED	Talk 2: PreTarg-it® - Radioimmunotherapy with bispecific antibodies for hard-to-treat cancers	Talk 8: Going from Preclinical to Clinical	Business of RLT	
10:25 – 11:05		Speaker: Christine Landlinger-Schubert Vice President Preclinical & Translational R&D OncoOne	Speaker: [TBD]	Talk 13: Current and practical bottlenecks on RLT development	
11:05 – 11:45		10 min discussion	10 min discussion	Speaker: Jeff Norenberg Co-Founder & CEO iSeek Biopharma	
		Discussion Panel 1:	Discussion Panel 3:	10 min discussion	
		Topic: Combination therapies and ideal schemes	Topic: Preparing to go the clinic – lessons learned	Talk 14: Bringing a novel drug to the clinics - a Business perspective	
				Speaker: Jeremy Paull Chief Scientific & Regulatory Officer Starpharma	
11:45 – 12:15				10 min discussion	
12:15 – 12:55			Coffee Break	Coffee Break	Coffee Break & bites
			Preclinical tools: models, isotopes & dosimetry	Preclinical vectors: targets and probes	RLT AI tools Session
			Talk 3: Animal Models to investigate your drug	Talk 9: Current and emerging targets for radiopharmaceutical therapy	Talk 15: AI tools currently deployed in RLT development and solutions they provide
		Speaker: Ada Repetto-Llamazares Chief Scientific Officer NucliThera	Speaker: Gareth Smith Biotech Strategy Telix Pharmaceuticals Limited	Speaker: [TBD]	
12:55 – 13:35		10 min discussion	10 min discussion	10 min discussion	
		Talk 4: Non-animal models to investigate your drug	Talk 10: Advances in probes for RLT	Discussion Panel 6:	
		Speaker: Teodor Yordanov Chief Scientific Officer Angios Biotech	Speaker: Anne Bredenbeck Senior Scientist Radiopharmaceutical Technologies 3B Pharmaceuticals	Topic: AI adoption	
13:35 – 14:15		10 min discussion	Discussion Panel 4: Topic: Targets & probes in RLT		
14:15 – 14:55		Lunch Break	Lunch Break		
		Talk 5: Exploring the ideal alpha isotope for targeted therapy	Talk 11: Imaging as a guide to RLT development	Lunch and Closing Ceremony	
		Speaker: Marion Malenge Head of in vivo Radiopharma Development ArtBio	Speaker: Syed Nurrudin Senior Researcher Norsk Medisinsk Syklotron Senter		
		10 min discussion	10 min discussion		
	Talk 6: Dosimetry - current status, challenges and translation aspects	Talk 12: Guiding RLT development through ADCs			
14:55 – 15:35		Speaker: Mark Konijnenberg Physicist Erasmus MC	Speaker: Sujiet Puthenveetil Director AstraZeneca		
15:35 – 16:00		10 min discussion	10 min discussion		
		Discussion Panel 2: Topic: a emitters + ideal isotopes for therapy	Discussion Panel 5: Topic: Guided from diagnostics to create therapeutics		
16:00 – 16:30					
19.00 - 21.00	Social Event	Wrap-Up & Closing Remarks	Wrap-Up & Closing Remarks		
		Social Event	Social Event		